Kronos Bio
KRON
KRON was delisted on the 20th of June, 2025.
87 hedge funds and large institutions have $47.3M invested in Kronos Bio in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 29 increasing their positions, 25 reducing their positions, and 18 closing their positions.
900% more call options, than puts
Call options by funds: $20K | Put options by funds: $2K
16% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 25
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4.43% less ownership
Funds ownership: 60.64% → 56.21% (-4.4%)
10% less funds holding
Funds holding: 97 → 87 (-10)
16% less capital invested
Capital invested by funds: $56.3M → $47.3M (-$8.93M)
56% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$383K |
| 2 |
Millennium Management
New York
|
+$344K |
| 3 |
JP Morgan Chase
New York
|
+$331K |
| 4 |
CM
CM Management
Gulf Breeze,
Florida
|
+$288K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$198K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$1.94M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.18M |
| 3 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$624K |
| 4 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$318K |
| 5 |
WCM
Wildcat Capital Management
New York
|
-$269K |
KRON Hedge Fund Activity: Q1 2023 in Review
87 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Kronos Bio (KRON) for Q1 2023, worth a combined $47.3M — down 16% from $56.3M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of KRON and 8 opened new positions — a net loss of 10 holders — while 25 trimmed existing stakes and 29 added.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $383K. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $1.94M sold.
- 87 institutional investors held Kronos Bio (KRON) as of Q1 2023, down from 97 in Q4 2022.
- Funds reported $47.3M of Kronos Bio stock for Q1 2023, down 16% quarter-over-quarter.
- 8 funds opened new Kronos Bio positions in Q1 2023 and 18 closed out, a net change of -10 holders.
- The largest Kronos Bio buyer in Q1 2023 was Tang Capital Management, an estimated $383K added.
- The largest Kronos Bio seller in Q1 2023 was Baker Bros. Advisors, an estimated $1.94M sold.
Based on aggregated 13F filings for Q1 2023.